1
|
Yang F, Zhu X, Li L, Wang Y, Xie Q, Cao Y, Yu Y, Zhang M, Li D, Li L, Liu Z, Zhang B, Chen Z, Deng S, Li Y. SDH, a novel diarylheptane compound, is a potential treatment for inflammatory bowel disease by restoring epithelial barrier function. Biomed Pharmacother 2022; 151:113080. [PMID: 35561427 DOI: 10.1016/j.biopha.2022.113080] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2022] [Revised: 04/27/2022] [Accepted: 05/04/2022] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND The global prevalence of inflammatory bowel disease (IBD) is increasing, and mucosal healing is the preferred treatment target of IBD. Sodium (aS,9 R)- 3-hydroxy-16,17-dimethoxy-15-oxidotricyclo[12.3.1.12,6]nonadeca-1(18),2,4,6(19),14,16-hexene-9-yl sulfate hydrate (SDH) is a novel diarylheptane compound, which is designed to treat IBD. Hence, we investigated the potent therapeutic activity of SDH against IBD and explored the underlying mechanisms, and determined if SDH is a safe and well-tolerated oral therapeutic for IBD treatment. METHODS We characterized its therapeutic properties in vitro and in vivo using Caco-2 cell monolayer and dextran sodium sulfate (DSS)- or 2,4,6-trinitro-benzene sulfonic acid (TNBS)-induced colitis models. We conducted nonclinical toxicology and safety pharmacology research, including general toxicity, toxicokinetics, pharmacokinetics, metabolism and plasma protein binding, cardiovascular safety pharmacology, central nervous system safety pharmacology, respiratory safety pharmacology, fertility and early embryonic development toxicity, reverse mutation assay, chromosomal aberration assay and micronucleus test. RESULTS The results showed that SDH promoted expression of tight junction proteins, and protected the integrity and permeability of the epithelial barrier in both cell and animal models. Moreover, lower doses of SDH showed the similar or better efficacy than cyclosporine A (CsA) and mesalazine in DSS- or TNBS-induced colitis animals. Furthermore, our results identified that SDH has satisfactory safety in these studies we tested. In summary, SDH restored the epithelial barrier through tight junction proteins and was expected to be a novel therapeutic agent for the treatment of IBD.
Collapse
Affiliation(s)
- Fei Yang
- Institutes of Biology and Medical Sciences, Soochow University, Suzhou, Jiangsu 215123, China; Suzhou Pharmavan Co.,Ltd, Suzhou, Jiangsu 215127, China.
| | - Xiaoqiang Zhu
- Suzhou Pharmavan Co.,Ltd, Suzhou, Jiangsu 215127, China.
| | - Liu Li
- Institutes of Biology and Medical Sciences, Soochow University, Suzhou, Jiangsu 215123, China.
| | - Yanping Wang
- Institutes of Biology and Medical Sciences, Soochow University, Suzhou, Jiangsu 215123, China.
| | - Qing Xie
- Institutes of Biology and Medical Sciences, Soochow University, Suzhou, Jiangsu 215123, China.
| | - Yu Cao
- Suzhou Pharmavan Co.,Ltd, Suzhou, Jiangsu 215127, China.
| | - Yunhui Yu
- Suzhou Pharmavan Co.,Ltd, Suzhou, Jiangsu 215127, China.
| | - Minjie Zhang
- Suzhou Pharmavan Co.,Ltd, Suzhou, Jiangsu 215127, China.
| | - Dong Li
- Suzhou Pharmavan Co.,Ltd, Suzhou, Jiangsu 215127, China.
| | - Ling Li
- Suzhou Pharmavan Co.,Ltd, Suzhou, Jiangsu 215127, China.
| | - Zhongtian Liu
- Suzhou Pharmavan Co.,Ltd, Suzhou, Jiangsu 215127, China.
| | - Biyan Zhang
- Suzhou Pharmavan Co.,Ltd, Suzhou, Jiangsu 215127, China.
| | - Zijun Chen
- School of Basic Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.
| | - Shiping Deng
- Suzhou Pharmavan Co.,Ltd, Suzhou, Jiangsu 215127, China.
| | - Yunsen Li
- Institutes of Biology and Medical Sciences, Soochow University, Suzhou, Jiangsu 215123, China.
| |
Collapse
|